THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION
Main Article Content
Keywords
JAK2V617F, Osteoclast, Myeloproliferative Neoplasm
Abstract
JAK2V617F is a gain of function point mutation that occurs in Myeloproliferative Neoplasm (MPN) patients and deranges their hemopoiesis at cellular level. We speculate that hyperfunctioning JAK2 can modify osteoclast (OCL) homeostasis in MPN patients. We studied 18 newly diagnosed MPN patients and four age-matched normal donors (ND). Osteoclast forming assays started from selected monocytes also and under titrated concentrations of the JAK2 Inhibitor AG-490 (Tyrphostin). Genomic DNA was extracted from the formed osteoclasts, and the JAK2V617F/JAK2WT genomic DNA ratio was calculated. OCLs formed from monocytes derived from heterozygous (Het) for the JAK2V617F mutation MPN patients, were three times more compared to those from JAK2 wild type (WT) MPN patients (p=0,05) and from ND as well (p=0,03). The ratio of JAK2V617F/JAK2WT genomic DNA was increased in OCLs compared to the input monocyte cells showing a survival advantage of the mutated clone. In comparison to ND and JAK2 WT MPN patients, OCLs from patients JAK2V617F (Het) were more susceptible to JAK2 inhibition. These alterations in osteoclast homeostasis, attributed to mutated JAK2, can deregulate the hemopoietic stem cell niche in MPN patients.
Downloads
Abstract 933
PDF Downloads 610
HTML Downloads 111
References
2. Mansour A, Abou-Ezzi G, Sitnicka E, W Jacobsen SE, Wakkach A, Blin-Wakkach C.Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. J Exp Med. 2012 Mar 12;209(3):537-49.
3. Lymperi S, Ersek A, Ferraro F, Dazzi F, Horwood NJ. Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood. 2011 Feb 3;117(5):1540-9.
4. Miyamoto K, Yoshida S, Kawasumi M, Hashimoto K, Kimura T, Sato Y, Kobayashi T, Miyauchi Y, Hoshi H, Iwasaki R, Miyamoto H, Hao W, Morioka H, Chiba K, Kobayashi T, Yasuda H, Penninger JM, Toyama Y, Suda T, Miyamoto T. Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J Exp Med. 2011 Oct 24; 208(11):2175-81.
5. Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, Tesio M, Samstein RM, Goichberg P, Spiegel A, Elson A, Lapidot T. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med. 2006 Jun;12(6):657-64.
6. Flores C, Moscatelli I, Thudium CS, Gudmann NS, Thomsen JS, Bruel A, Karsdal MA, Henriksen K, Richter J (2013) Osteoclasts are not crucial for hematopoietic stem cell maintenance in adult mice. Haematologica 98(12):1848–1855. doi:10.3324/haematol. 2013.089466 41. Bruns I, Lucas D, Pinho S, Ahmed J, Lambert MP
7. Rawlings JS, Rosler KM, Harrison DA, The JAK/STAT signaling pathway. J Cell Sci. 2004; 117: 1281– 1283. https://doi.org/10.1242/jcs.00963 PMID: 15020666
8. Murray PJ, The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007; 178: 2623–2629. PMID: 17312100
9. Mead AJ, Chowdhury O, Pecquet C, Dusa A, Woll P, Atkinson D, Burns A, Score J, Rugless M, Clifford R, Moule S, Bienz N, Vyas P, Cross N, Gale RE, Henderson S, Constantinescu SN, Schuh A, Jacobsen SE. impact of germline JAKV617F mutation in human hematopoiesis. Blood. 2013 May 16;121(20):4156-65.
10. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, Vanelli L, Arcaini L, Burcheri S, Malcovati L, Lazzarino M, Cazzola M.Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006 May 1;107(9):3676-82.
11. Kwak HB, Kim HS, Lee MS, Kim KJ, Choi EY, Choi MK, Kim JJ, Cho HJ, Kim JW, Bae JM, Kim YK, Park BH, Ha H, Chun CH, Oh J. Pyridone 6, a pan-Janus-activated kinase inhibitor, suppresses osteoclast formation and bone resorption through down-regulation of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL)-induced c-Fos and nuclear factor of activated T cells (NFAT) c1 expression. Biol Pharm Bull. 2009 Jan;32(1):45-50.
12. Li CH, Zhao JX, Sun L, Yao ZQ, Deng XL, Liu R, Liu XY. AG490 inhibits NFATc1expression and STAT3 activation during RANKL induced osteoclastogenesis. Biochem Biophys Res Commun 2013 jun 14: 435(4):533-9.
13. Jin-il Park, Jennifer Lee, Mi-Ae Lim, Eun Kyung Kim, Sung Min Kim, JunGeol Ryu, Jae Ho Lee, Seung-Ki Kwok, kyung-Su Park, Ho-Youn Kim, Sung-Hwan Park, Mi-La Cho. JAK2-STAT3 Blockade by AG490 Supresses autoimmune arthritis in mice via reciprocal regulation of T cells and Th17 cells. Journal of Immunology 2014; 192:4417-24.
14. Murakami K, Kobayashi Y, Uehara S, Suzuki T, Koide M, Yamashita T, et al. (2017) A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro. PLoS ONE 12(7): e0181126. https://doi.org/10.1371/journal. pone.0181126
15. S. Hiram-Bab, T Liron, N Deshet-Unger, M Mittelman, M Gassmann, M Raunner, K Franke, B Wieleckx, D Neumann, Y Gabet. Erythropoietin directly stimulates osteoclast precursors and induces bone loss. The FASEB Journal 2015; 29(5): 1890-1900.
16. Arranz L, Sanchez-Aguilera A, Martin-Perez D, Isern J, Langa X, Tzankov A, Lundberg P, Muntion S, Tzeng YS, Lai DM, Schwaller J, Skoda RC, Mendez-Ferrer S (2014) Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. doi:10.1038/nature13383
17. LaBranche TP, Jesson MI, Radi ZA, Storer CE, Guzova JA, Bonar SL, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheumatol. 2012; 64: 3531–3542.
18. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010; 184: 5298–5307. https://doi.org/10.4049/jimmunol.0902819 PMID: 20363976
19. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, del Carmen ML, Reyes GJ, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376: 652–662. pmid:28199814